Education
About Us
Working with TipRanks
Follow Us
Artivion (AORT)
NYSE:AORT
AORT Stock Chart & Stats
$47.50
$0.30(1.03%)
At close: 4:00 PM EST
$47.50
$0.30(1.03%)
Day’s Range― - ―
52-Week Range$21.97 - $47.69
Previous CloseN/A
Volume97.41K
Average Volume (3M)340.46K
Market Cap
$2.19B
Enterprise ValueN/A
Total Cash (Recent Filing)$53.48M
Total Debt (Recent Filing)$8.79M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Feb 12, 2026EPS Estimate
0.07Last Dividend Ex-Date
Dec 09, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding47,183,660
10 Day Avg. Volume425,379
30 Day Avg. Volume340,456
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$51.71Price Target Upside8.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsArtivion reported a strong Q3, with a beat fueled by growth in both the aortic stent graft business and On-X.
Pipeline And ApprovalArtivion received IDE approval for Arcevo LSA, its third-generation Frozen Elephant Trunk product, which replaces the entire aortic arch in acute and chronic pathologies.
Product LaunchThe AMDS acute type A aortic dissection repair device US launch is developing positively, with many sites adopting the system, supporting Artivion's growth.
Bears Say
Artivion News
AORT FAQ
What was Artivion’s price range in the past 12 months?
Artivion lowest stock price was $21.97 and its highest was $47.69 in the past 12 months.
What is Artivion’s market cap?
Artivion’s market cap is $2.19B.
When is Artivion’s upcoming earnings report date?
Artivion’s upcoming earnings report date is Feb 12, 2026 which is in 96 days.
How were Artivion’s earnings last quarter?
Artivion released its earnings results on Nov 06, 2025. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.017 by $0.113.
Is Artivion overvalued?
According to Wall Street analysts Artivion’s price is currently Undervalued.
Does Artivion pay dividends?
Artivion pays a Quarterly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Artivion dividends here
What is Artivion’s EPS estimate?
Artivion’s EPS estimate is 0.07.
How many shares outstanding does Artivion have?
Artivion has 47,183,660 shares outstanding.
What happened to Artivion’s price movement after its last earnings report?
Artivion reported an EPS of $0.13 in its last earnings report, beating expectations of $0.017. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Artivion?
Currently, no hedge funds are holding shares in AORT
Artivion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.71 (8.86% Upside)
$51.71 (8.86% Upside)
Blogger Sentiment
Bullish
AORT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 67.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.34%
12-Months-Change
Fundamentals
Return on Equity
-5.01%
Trailing 12-Months
Asset Growth
6.19%
Trailing 12-Months
Company Description
Artivion
Artivion, Inc. (AORT) is a medical technology company specializing in the development and commercialization of innovative surgical solutions for the treatment of cardiovascular diseases. The company primarily focuses on advanced bioengineered heart valves and minimally invasive surgical technologies, aiming to improve patient outcomes and reduce healthcare costs. Artivion's core products include its AORTIC® and PERIMOUNT® heart valve offerings, as well as its innovative surgical devices that are designed to assist in various cardiovascular procedures.
AORT Company Deck
AORT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong quarter with significant revenue and EBITDA growth driven by key product lines. Positive clinical data and reimbursement updates further strengthen the company's position. However, challenges include costs related to a past cybersecurity incident and expected growth rate challenges for AMDS in 2026.View all AORT earnings summariesAORT Stock 12 Month Forecast
Average Price Target
$51.71
▲(8.86% Upside)
Technical Analysis
Ownership Overview
4.87% Insiders
30.15% Mutual Funds
0.02% Other Institutional Investors
46.37% Public Companies and
Individual Investors